AMERICAN JOURNAL OF HEMATOLOGY

Scope & Guideline

Pioneering Insights for Tomorrow's Hematology

Introduction

Immerse yourself in the scholarly insights of AMERICAN JOURNAL OF HEMATOLOGY with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN0361-8609
PublisherWILEY
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1976 to 2024
AbbreviationAM J HEMATOL / Am. J. Hematol.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address111 RIVER ST, HOBOKEN 07030-5774, NJ

Aims and Scopes

The American Journal of Hematology focuses on advancing the understanding and treatment of blood disorders through rigorous research and clinical studies. Its scope encompasses a wide range of hematological conditions and therapeutic approaches, with a commitment to disseminating findings that have a significant impact on patient care and outcomes.
  1. Hematological Malignancies:
    The journal extensively covers research on leukemia, lymphoma, and myeloma, focusing on novel therapies, clinical trials, and molecular genetics that influence treatment and prognosis.
  2. Transfusion Medicine:
    Research related to transfusion practices, blood safety, and the management of transfusion-related complications is a key area, reflecting the journal's commitment to improving patient care in transfusion settings.
  3. Sickle Cell Disease and Thalassemia:
    Papers often explore the pathophysiology, management strategies, and innovative therapies for sickle cell disease and thalassemia, aiming to improve health outcomes for affected individuals.
  4. Coagulation Disorders:
    The journal includes research on various coagulation disorders, including hemophilia and thrombosis, focusing on new treatment modalities and strategies for management.
  5. Stem Cell Transplantation:
    There is a significant emphasis on studies related to hematopoietic stem cell transplantation, including donor selection, conditioning regimens, and post-transplant outcomes.
  6. Clinical Trials and Therapeutics:
    The journal publishes findings from clinical trials of new drugs, treatment regimens, and innovative therapies, contributing to the evidence base for clinical practice.
The American Journal of Hematology has seen a rise in interest in several emerging themes and trends that reflect the evolving landscape of hematological research and patient care. These include advancements in technology and novel therapeutic approaches.
  1. Immunotherapy and CAR-T Cell Therapy:
    There is a growing emphasis on the development and application of immunotherapies, particularly CAR-T cell therapies, for hematological malignancies, showcasing innovative treatment options.
  2. Targeted Therapy and Precision Medicine:
    Research focusing on targeted therapies based on genetic and molecular profiling of hematological disorders is on the rise, reflecting a shift towards personalized treatment approaches.
  3. Biomarkers and Minimal Residual Disease Monitoring:
    Emerging studies are increasingly focusing on the identification and utilization of biomarkers for disease monitoring and prognosis, particularly in acute myeloid leukemia and other malignancies.
  4. Health Disparities and Patient-Centered Care:
    The journal is increasingly addressing health disparities within hematology, emphasizing the importance of equitable care and patient-reported outcomes in treatment strategies.
  5. Long-term Effects of COVID-19 on Hematology Patients:
    Research exploring the implications of COVID-19 on patients with existing hematological conditions, including vaccine responses and management challenges, has gained prominence.
  6. Artificial Intelligence and Machine Learning in Hematology:
    There is a notable trend towards integrating artificial intelligence and machine learning into hematology research, particularly in diagnostics and treatment personalization.

Declining or Waning

While the American Journal of Hematology continues to be a leading publication in the field, certain topics have seen a decline in focus over recent years. This may reflect shifts in research priorities or advancements in understanding that have lessened the need for certain types of studies.
  1. Traditional Chemotherapy Approaches:
    There is a noticeable decrease in studies focusing solely on traditional chemotherapy regimens as the field moves towards targeted therapies and immunotherapies, which are now the focus of many clinical trials.
  2. Basic Science Research:
    The journal has shifted towards more clinically relevant studies, with a waning interest in purely basic science research that does not directly translate to clinical applications.
  3. Epidemiological Studies:
    Although still important, there appears to be a reduction in the volume of studies that solely focus on the epidemiology of hematological disorders, as the emphasis shifts towards treatment outcomes and therapeutic innovations.
  4. Longitudinal Studies in Hematology:
    Fewer longitudinal studies are being published, as funding and interest may be shifting towards more immediate, impactful clinical trials and translational research.

Similar Journals

Experimental Hematology & Oncology

Driving Progress in Blood Health and Cancer Solutions
Publisher: BMCISSN: Frequency: 1 issue/year

Experimental Hematology & Oncology is a premier journal published by BMC, dedicated to advancing knowledge in the fields of hematology, oncology, and cancer research. Since its inception in 2012, this Open Access journal has emerged as a vital resource for researchers and healthcare professionals, fostering the dissemination of high-quality research that enhances our understanding of blood disorders and malignancies. With impressive rankings in Quarters 1 of key categories including Cancer Research, Hematology, and Oncology, it holds significant prestige, evidenced by its Scopus rankings: #42/404 in Medicine (Oncology) and #17/137 in Medicine (Hematology). The journal aims to publish cutting-edge studies, reviews, and perspectives that contribute to the evolution of therapeutic strategies and innovative treatment modalities. Researchers and practitioners alike will find this journal indispensable for staying at the forefront of breakthroughs in hematological and oncological research.

Iraqi Journal of Hematology

Unveiling Breakthroughs in Blood Disorders
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 2072-8069Frequency: 2 issues/year

Iraqi Journal of Hematology is a prominent peer-reviewed open-access journal dedicated to advancing the field of hematology. Published by Wolters Kluwer Medknow Publications, this journal provides a platform for researchers, professionals, and students to share cutting-edge findings and developments in various aspects of hematology, including blood diseases, diagnostics, and innovative treatments. Since its transition to open access in 2016, the journal has significantly increased its reach, allowing for wider dissemination of critical research to a global audience. With an ISSN of 2072-8069 and an E-ISSN of 2543-2702, the Iraqi Journal of Hematology strives to adhere to the highest scholarly standards and plays a vital role in the ongoing discourse in hematological research. Researchers are encouraged to contribute to this essential resource for the scientific community, contributing to the advancement of knowledge that ultimately improves patient care and treatment outcomes.

BONE MARROW TRANSPLANTATION

Connecting Researchers to Transform Transplantation Practices.
Publisher: SPRINGERNATUREISSN: 0268-3369Frequency: 12 issues/year

BONE MARROW TRANSPLANTATION, published by SpringerNature, stands as a leading journal in the fields of Hematology and Transplantation, as evidenced by its recognition in the Q1 category for both disciplines according to 2023 rankings. With an impressive impact factor and notable Scopus rankings—7th out of 54 in Medicine Transplantation and 25th out of 137 in Medicine Hematology—this journal is instrumental for researchers and professionals dedicated to advancements in bone marrow transplantation practices and research. Established in 1986, the journal publishes original research, clinical studies, and reviews that push the boundaries of current knowledge, making it essential reading for those looking to stay abreast of the latest developments in the field. Although offering limited Open Access options, BONE MARROW TRANSPLANTATION reaches a broad audience and furthers a global dialogue on best practices and innovative approaches in transplantation medicine. Its address in London, UK positions it at the heart of international research collaboration, fostering connections among scientists, clinicians, and students alike.

Journal of Blood Medicine

Elevating Standards: The Premier Source for Blood Medicine Insights
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-2736Frequency: 1 issue/year

The Journal of Blood Medicine, published by DOVE MEDICAL PRESS LTD, stands as a vital resource in the field of hematology, focusing on the latest research developments and clinical advancements in blood medicine. With an impact factor reflective of its growing relevance, this open-access journal has been delivering quality scholarly work since 2010, ensuring that critical research is readily available to the global scientific community. The journal operates under an open-access model, further enhancing its dissemination and accessibility to researchers, professionals, and students alike. In the 2023 rankings, it secured a Q3 category status within hematology and achieved a commendable 76th rank out of 137 in Scopus listings, indicating its commitment to quality and innovation in this specialized area. Located in New Zealand, the journal's diverse topics encompass clinical research, treatment modalities, and emerging therapies, contributing significant insights vital for shaping future advancements in blood medicine.

HemaSphere

Delivering cutting-edge insights to the hematology community.
Publisher: WILEYISSN: Frequency: 12 issues/year

HemaSphere, published by WILEY, stands at the forefront of hematology research, offering a vital platform for the dissemination of cutting-edge findings in the field. Since its inception in 2017 and official transition to Open Access in 2018, the journal has positioned itself as a leading conduit for high-impact research, maintaining a prestigious Q1 quartile ranking in the Hematology category as of 2023. Addressed in the United States at 111 River St, Hoboken, NJ, HemaSphere aims to foster a global dialogue among researchers, clinicians, and students by providing unrestricted access to high-quality content that encompasses clinical and experimental advancements. With an array of engaging articles, reviews, and commentaries, HemaSphere contributes significantly to the advancement of hematology, ensuring that critical knowledge is readily accessible to enhance patient care and innovative research. To explore the latest developments and breakthroughs in this dynamic field, we invite scholars, professionals, and students to engage with HemaSphere and elevate their understanding of hematologic science.

Therapeutic Advances in Hematology

Elevating therapeutic practices in hematology.
Publisher: SAGE PUBLICATIONS LTDISSN: 2040-6207Frequency: 1 issue/year

Therapeutic Advances in Hematology is a prestigious, peer-reviewed journal dedicated to advancing the field of hematology through innovative research and clinical studies. Published by SAGE Publications Ltd, this journal has become a vital resource for hematology professionals and researchers since its inception in 2010. With its impactful Q1 ranking in Hematology and a Scopus rank of 62 out of 137, it firmly establishes itself as a leader in disseminating significant findings and therapeutic approaches. The journal has been committed to open access since 2019, ensuring that its cutting-edge research is readily available to the global scientific community. Covering a broad scope of topics within hematology, Therapeutic Advances in Hematology is an essential platform for those seeking to enhance their understanding and implementation of therapeutic practices in hematological conditions. The journal embraces submissions from both clinical and laboratory perspectives, fostering collaboration and dialogue among researchers, clinicians, and students alike.

Blood Research

Connecting Researchers to Revolutionize Blood Health
Publisher: SPRINGERISSN: 2287-979XFrequency: 4 issues/year

Blood Research, published by SPRINGER, is a premier journal dedicated to the multifaceted realm of hematology, serving as a crucial platform for disseminating innovative research findings and advancements in the diagnosis and treatment of blood-related disorders. With an ISSN of 2287-979X and an E-ISSN of 2288-0011, this journal is recognized for its commitment to scholarly excellence and impact in the field, currently holding a reputable Q2 ranking in the Hematology category as per the 2023 metrics. The journal spans from 2013 to 2024, providing a broad archive of quality research that is vital for researchers, healthcare professionals, and students alike. Although it is not an Open Access journal, it offers insightful contributions that enhance the understanding of hematological science, fostering the exchange of knowledge crucial for advancing patient care and clinical practices globally. The journal’s performance is underscored by its Scopus ranking in the 46th percentile, reflecting its significant role in the ongoing discourse in hematology.

Transfusionsmedizin

Elevating transfusion practices through peer-reviewed excellence.
Publisher: GEORG THIEME VERLAG KGISSN: 2191-8805Frequency: 4 issues/year

Transfusionsmedizin is a premier journal dedicated to the field of transfusion medicine, published by the renowned GEORG THIEME VERLAG KG. With an ISSN of 2191-8805 and an E-ISSN of 2191-8813, this journal serves as a vital platform for disseminating cutting-edge research and clinical advancements in blood transfusion practices. Although it operates under a subscription model, the journal is committed to high-quality peer-reviewed content that addresses contemporary challenges and innovations in transfusion therapy. By fostering dialogue among researchers, clinicians, and students, Transfusionsmedizin aims to advance patient care and enhance the safety and efficacy of transfusion practices globally. Its contributions are essential for professionals engaged in transfusion science, hematology, and related medical fields, solidifying its reputation as a critical resource for staying abreast of the latest developments in transfusion research.

PEDIATRIC HEMATOLOGY AND ONCOLOGY

Empowering healthcare through cutting-edge pediatric studies.
Publisher: TAYLOR & FRANCIS INCISSN: 0888-0018Frequency: 8 issues/year

Pediatric Hematology and Oncology, published by Taylor & Francis Inc, serves as a vital platform dedicated to the fields of hematology, oncology, and pediatrics, providing a comprehensive avenue for the dissemination of scholarly research and clinical advancements. With an ISSN of 0888-0018 and an E-ISSN of 1521-0669, this journal has successfully converged its expertise over the years from 1984 to 2024. Ranked in the Q3 category for Hematology and Oncology, alongside a Q2 ranking in Pediatrics, Perinatology, and Child Health (2023), it engages a diverse readership comprising researchers, healthcare professionals, and students eager to explore groundbreaking studies in child health and treatment methodologies. While it currently does not offer Open Access options, the journal is widely cited and recognized, particularly in its specialized fields, fostering a rich environment for dialogue and innovation in the management of pediatric hematological and oncological disorders. The journal is based in the United Kingdom at 530 Walnut Street, Ste 850, Philadelphia, PA 19106, making it an essential resource for those pursuing excellence in pediatric medical research.

INTERNATIONAL JOURNAL OF HEMATOLOGY

Exploring Breakthroughs in Blood Disorders
Publisher: SPRINGER JAPAN KKISSN: 0925-5710Frequency: 12 issues/year

The INTERNATIONAL JOURNAL OF HEMATOLOGY, published by SPRINGER JAPAN KK, serves as a critical platform for advancing research in the field of hematology. With a prestigious history spanning over three decades from 1991 to 2024, this journal is recognized for its impactful contributions, evidenced by its Q2 category ranking in Hematology for 2023, and its notable position at rank #71 out of 137 in the Scopus Medicine Hematology category. Researchers and professionals within the hematology community benefit from the journal's rigorous peer-reviewed articles that cover a wide range of topics, including clinical studies, basic research, and novel therapeutic strategies. Though currently non-open access, it provides essential insights and findings to an audience passionate about the latest advancements in blood disorders and treatments. Situated in Japan, the journal not only showcases high-quality research but also fosters a global exchange of knowledge in hematology, making it a significant resource for scholars, practitioners, and students alike.